Global Antibody Drug Conjugates Contract Manufacturing Market, By Condition (Myeloma, Lymphoma, Breast Cancer, Others (Urothelial Cancer), Linker (Cleavable Linker, Non-cleavable) – Industry Trends and Forecast to 2029
Antibody Drug Conjugates Contract Manufacturing Market Analysis and Size
Drug and antibody conjugate. ADCs, also known as antibody-drug conjugates, are a family of biopharmaceutical medications created as a targeted therapy for cancer treatment. ADCs are designed to target and destroy tumour cells while protecting healthy cells, in contrast to chemotherapy.
Data Bridge Market Research analyses that the antibody drug conjugates contract manufacturing market which was USD 8.2 billion in 2021, would rocket up to USD 12.35 billion by 2029, and is expected to undergo a CAGR of 5.25% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Antibody Drug Conjugates Contract Manufacturing Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Condition (Myeloma, Lymphoma, Breast Cancer, Others (Urothelial Cancer), Linker (Cleavable Linker, Non-cleavable)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Samsung Biologics (South Korea), Lonza (Switzerland), Catalent Inc. (U.S.), Siegfried Holding AG (Switzerland), Piramal Pharma Solutions (India), Boehringer Ingelheim International GmbH (Germany)
|
|
Market Opportunities
|
|
Market Definition
One of the anticancer medications with the quickest growth is antibody-drug conjugates (ADC). This method uses a mAb attached to a lethal payload via a chemical linker that is directed at a target antigen expressed on the surface of the cancer cell, limiting systemic exposure and toxicity. ADCs are intricate molecules that need special consideration for a number of factors.
Antibody Drug Conjugates Contract Manufacturing Market Dynamics
Drivers
- Increase in demand of medicines
The market's growth is primarily driven by two factors: the increase in the need for medicines on a global scale and the advantage of lower total development costs with contract manufacturing.
- Rise in the geriatric population
The rising prevalence rates of lifestyle disorders like rising health-care spending, and the fast-growing diagnostic industry are driving the antibody drug conjugates contract manufacturing market expansion.
Opportunities
- Rise in cancer cases
The market is predicted to have considerable expansion over the course of the forecast period due to factors including rising need for biologic therapy, rising cancer prevalence, and outsourcing of operations and services to contract manufacturing companies.
Restraints/Challenges
The high cost of medicine development and distribution, on the other hand, will impede the market's rate of expansion. The market will be challenged by the shortage of trained personnel and inadequate healthcare infrastructure in developing nations.
This antibody drug conjugates contract manufacturing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the antibody drug conjugates contract manufacturing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Antibody Drug Conjugates Contract Manufacturing Market
The COVID-19 pandemic prompted the creation of COVID-19 vaccinations, antibody treatments, antiviral medications, and numerous other associated pharmaceutical items. Brazil, India, the United States, and several important European nations were severely affected by the epidemic, which increased demand for biopharmaceutical goods and, as a result, medicine production. To assure the quality and safety of their products, vaccines and biologics require specialised production and fill-finish techniques. This calls for highly developed analytical skills and flexible aseptic fill-finish technology. As a result, covid-19 had a favourable effect on the market.
Global Antibody Drug Conjugates Contract Manufacturing Market Scope
The antibody drug conjugates contract manufacturing market is segmented on the basis of condition, linker. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Condition
- Myeloma
- Lymphoma
- Breast Cancer
- Others (Urothelial Cancer)
Linker
- Cleavable Linker
- Non-cleavable Linker
Antibody Drug Conjugates Contract Manufacturing Market Regional Analysis/Insights
The antibody drug conjugates contract manufacturing market is analysed and market size insights and trends are provided by country, condition, linker as referenced above.
The countries covered in the antibody drug conjugates contract manufacturing market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the antibody drug conjugates contract manufacturing market due to the growing number of geriatric population along with adoption of innovative medical technology.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the increase in the outsourcing operations to contract manufacturing organizations.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Antibody Drug Conjugates Contract Manufacturing Market Share Analysis
The antibody drug conjugates contract manufacturing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to antibody drug conjugates contract manufacturing market.
Some of the major players operating in the antibody drug conjugates contract manufacturing market are:
- Samsung Biologics (South Korea)
- Lonza (Switzerland)
- Catalent Inc. (U.S.)
- Siegfried Holding AG (Switzerland)
- Piramal Pharma Solutions (India)
- Boehringer Ingelheim International GmbH (Germany)
SKU-